Sonja Heibl

1.1k total citations
21 papers, 155 citations indexed

About

Sonja Heibl is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Sonja Heibl has authored 21 papers receiving a total of 155 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Genetics and 8 papers in Oncology. Recurrent topics in Sonja Heibl's work include Advanced Breast Cancer Therapies (5 papers), Acute Myeloid Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (5 papers). Sonja Heibl is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Acute Myeloid Leukemia Research (5 papers) and Cancer Treatment and Pharmacology (5 papers). Sonja Heibl collaborates with scholars based in Austria, Switzerland and Greece. Sonja Heibl's co-authors include Gabriel Rinnerthaler, Christopher Hager, Christoph Tinchon, Michael Hubalek, Christian F. Singer, Johannes Andel, Michael Knauer, Marija Balić, Daniel Egle and Andreas Petzer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sonja Heibl

15 papers receiving 151 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonja Heibl Austria	7	103	60	53	37	36	21	155
Hans Wildiers Belgium	4	189 1.8×	56 0.9×	79 1.5×	17 0.5×	50 1.4×	10	233
Ivelise Rijo United States	5	45 0.4×	31 0.5×	38 0.7×	38 1.0×	14 0.4×	7	126
Carlos Dzik Brazil	9	44 0.4×	48 0.8×	94 1.8×	24 0.6×	29 0.8×	26	151
Jason Mouabbi United States	7	113 1.1×	100 1.7×	64 1.2×	13 0.4×	51 1.4×	41	205
Kit Fuhrman United States	4	95 0.9×	30 0.5×	31 0.6×	25 0.7×	22 0.6×	8	153
Donata Sartori Italy	6	72 0.7×	51 0.8×	36 0.7×	15 0.4×	13 0.4×	18	126
Tetsuhiro Yoshinami Japan	6	116 1.1×	50 0.8×	53 1.0×	12 0.3×	18 0.5×	48	174
Brooke Daniel United States	7	170 1.7×	58 1.0×	69 1.3×	17 0.5×	33 0.9×	17	196
Benjamin Y. Tan Singapore	10	73 0.7×	93 1.6×	38 0.7×	10 0.3×	36 1.0×	20	213
Francesca Daniel Italy	7	123 1.2×	68 1.1×	56 1.1×	7 0.2×	23 0.6×	21	180

Countries citing papers authored by Sonja Heibl

Since Specialization

Citations

This map shows the geographic impact of Sonja Heibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja Heibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja Heibl more than expected).

Fields of papers citing papers by Sonja Heibl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja Heibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja Heibl. The network helps show where Sonja Heibl may publish in the future.

Co-authorship network of co-authors of Sonja Heibl

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja Heibl. A scholar is included among the top collaborators of Sonja Heibl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja Heibl. Sonja Heibl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heibl, Sonja, et al.. (2025). The impact of mutational burden, spliceosome and epigenetic regulator mutations on transfusion dependency in dysplastic neoplasms. Journal of Laboratory Medicine. 49(2). 63–70.

Bartsch, Rupert, Zsuzsanna Bagó-Horváth, Daniel Egle, et al.. (2025). New Perspectives in the Management of Triple-Negative Breast Cancer. Breast Care. 1–14.

Gnant, Michael, Marija Balić, Gabriel Rinnerthaler, et al.. (2024). Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer. memo - Magazine of European Medical Oncology. 18(1). 4–18.

Heibl, Sonja, et al.. (2024). Functional Precision Medicine Successfully Guides Therapeutic Regimen of ‘Cancer of Unknown Primary’ Later Classified as Triple-Negative Breast Cancer: A Case Report. SHILAP Revista de lepidopterología. 17(1). 490–496.

Bartsch, Rupert, Simon Peter Gampenrieder, Daniel Egle, et al.. (2024). Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression. Molecular Oncology. 19(7). 1897–1917. 6 indexed citations

Kühr, Thomas, et al.. (2023). Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review. Frontiers in Oncology. 13. 1166545–1166545. 6 indexed citations

Gampenrieder, Simon Peter, Gabriel Rinnerthaler, Christoph Tinchon, et al.. (2022). Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry. Cancer Research. 82(4_Supplement). P1–21. 1 indexed citations

Heibl, Sonja. (2021). Is it time for interferon in low-risk patients with polycythaemia vera?. The Lancet Haematology. 8(3). e162–e163. 2 indexed citations

Heibl, Sonja, Reinhard Stauder, & Michael Pfeilstöcker. (2021). Is Myelodysplasia a Consequence of Normal Aging?. Current Oncology Reports. 23(12). 142–142. 6 indexed citations

10.

Gampenrieder, Simon Peter, Gabriel Rinnerthaler, Christoph Tinchon, et al.. (2021). Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Research. 23(1). 112–112. 94 indexed citations

11.

Rinnerthaler, Gabriel, Simon Peter Gampenrieder, Christoph Tinchon, et al.. (2021). Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry. Cancer Research. 81(4_Supplement). PS12–21. 1 indexed citations

12.

Heibl, Sonja, Bettina Gisslinger, Peter Bettelheim, et al.. (2020). Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. Cancers. 12(7). 1891–1891. 4 indexed citations

13.

Füreder, Wolfgang, Wolfgang R. Sperr, Sonja Heibl, et al.. (2020). Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network. Annals of Hematology. 99(10). 2303–2313. 8 indexed citations

14.

Heibl, Sonja, Veronika Buxhofer‐Ausch, Stefan Schmidt, et al.. (2020). A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1. Hematological Oncology. 38(5). 792–798. 6 indexed citations

15.

Buxhofer‐Ausch, Veronika, Dominik Wolf‎, Wolfgang Schimetta, et al.. (2020). Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia. European Journal Of Haematology. 106(1). 58–63. 13 indexed citations

16.

Buxhofer‐Ausch, Veronika, Sonja Heibl, Thamer Sliwa, et al.. (2020). Austrian recommendations for the management of essential thrombocythemia. Wiener klinische Wochenschrift. 133(1-2). 52–61. 1 indexed citations

17.

Holzner, Bernhard, Sonja Heibl, Monika Sztankay, et al.. (2020). Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot Study. Integrative Cancer Therapies. 19. 1872156890–1872156890. 4 indexed citations

18.

Caers, Jo, Xavier Leleu, Barbara Gamberi, et al.. (2019). Real-World Use of Carfilzomib Therapy Among Patients With Existing Cardiovascular Medical History: An Analysis of a Prospective Observational Study. Clinical Lymphoma Myeloma & Leukemia. 19(10). e281–e282.

19.

Terpos, Evangelos, Xavier Leleu, Barbara Gamberi, et al.. (2019). Real-World Evidence of the Use of Carfilzomib and Dexamethasone According to Age Subgroup: An Interim Analysis From a Prospective Observational Study. Clinical Lymphoma Myeloma & Leukemia. 19(10). e282–e283.

20.

Leleu, Xavier, Barbara Gamberi, Jo Caers, et al.. (2019). PF616 REAL‐WORLD USE OF THE TRIPLET REGIMEN CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A SUB‐GROUP INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY. HemaSphere. 3(S1). 262–262. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact